Axim CV 250 mg Tab

Axim CV 250 mg Tablet (Cefuroxime Axetil + Clavulanic Acid) — Clinical Overview

What is Axim CV 250 mg?

Axim CV 250 mg Tab is a combination antibiotic from ACI Limited, Bangladesh, containing two active components: cefuroxime axetil (a second-generation cephalosporin) and clavulanic acid (a beta-lactamase inhibitor). Together, they form a broader-spectrum antibiotic combination that can overcome certain types of bacterial antibiotic resistance that would otherwise render cefuroxime alone ineffective.

The "CV" suffix denotes Cefuroxime + claVulanate — similar to the "CV" naming convention used in amoxicillin-clavulanate (co-amoxiclav) products. Axim CV is prescribed when a more resistant bacterial infection is suspected or when standard cefuroxime has proven insufficient.

How Does the Combination Work?

Cefuroxime axetil kills bacteria by inhibiting cell wall synthesis through penicillin-binding protein (PBP) blockade — the same mechanism as all beta-lactam antibiotics. While cefuroxime is inherently more stable against many beta-lactamases than first-generation cephalosporins, certain bacteria produce more potent or higher-output beta-lactamases that can degrade cefuroxime.

Clavulanic acid acts as an irreversible, "suicide" inhibitor of beta-lactamase enzymes. It binds and permanently inactivates these enzymes, preventing them from breaking down cefuroxime. This extends effective bacterial coverage to organisms that produce certain types of beta-lactamases, including:

• TEM- and SHV-type beta-lactamases in Enterobacteriaceae
• Staphylococcal penicillinase (PC1 beta-lactamase)
• Beta-lactamases from H. influenzae and M. catarrhalis

Important limitation: Clavulanic acid does NOT inhibit extended-spectrum beta-lactamases (ESBLs) or carbapenemases (KPC, NDM). Infections caused by ESBL-producing E. coli or Klebsiella — increasingly common in Bangladesh — are NOT covered by Axim CV.

Clinical Indications

Axim CV 250 mg is indicated for mild-to-moderate bacterial infections caused by clavulanate-susceptible organisms:

• Respiratory tract infections: Acute sinusitis, acute exacerbations of chronic bronchitis (AECB), pharyngitis/tonsillitis caused by beta-lactamase-producing strains
• Urinary tract infections: Complicated UTIs where beta-lactamase-producing E. coli or Klebsiella are suspected
• Skin and soft tissue infections: Infected wounds, cellulitis, impetigo — including infections involving S. aureus producing staphylococcal penicillinase
• Dental and oral infections: Periodontal infections with mixed flora
• Diabetic foot infections (mild-to-moderate): Mixed bacterial infections where beta-lactamase producers may be involved

Special Relevance for Diabetic Patients

Patients with diabetes mellitus are disproportionately affected by infections caused by antibiotic-resistant organisms, due to glycosuria (which promotes bacterial growth), recurrent antibiotic exposure (selecting for resistant strains), and impaired immune clearance. Axim CV addresses several specific challenges:

• Complicated UTIs: Diabetic patients with recurrent UTIs often harbour beta-lactamase-producing E. coli that are resistant to plain amoxicillin and sometimes to plain cefuroxime. Axim CV can provide coverage for these intermediate-resistance strains — though ESBL-producing isolates (common in recurrent diabetic UTIs in South Asia) require different agents (nitrofurantoin, fosfomycin, or IV carbapenems).
• Diabetic foot infections (DFIs): Mild DFIs often involve mixed aerobic flora including S. aureus and Gram-negative rods. Axim CV's extended spectrum covers this polymicrobial profile better than plain cefuroxime.
• Recurrent skin infections: Repeated infections in diabetics may involve penicillinase-producing S. aureus. Axim CV covers this better than plain cefuroxime or amoxicillin alone.
• Antibiotic stewardship: While Axim CV offers broader coverage, using it empirically when plain cefuroxime would suffice accelerates resistance. Culture-guided prescribing is preferred, especially for UTIs in diabetics.

Dosage and Administration

• Standard adult dose: 250 mg tablet twice daily × 5–10 days (duration varies by infection type)
• Take with food: Both cefuroxime axetil and clavulanic acid are better absorbed with food, and clavulanate in particular causes significant nausea when taken on an empty stomach
• Swallow whole: Do not crush or chew — tablets have a film coating for delayed release and flavour masking
• Complete the full course as prescribed

Drug Interactions

• Warfarin / anticoagulants: Cefuroxime-clavulanate may potentiate anticoagulant effects; monitor INR closely
• Probenecid: Increases cefuroxime plasma levels; clavulanate levels also affected
• PPIs / antacids: May reduce cefuroxime axetil absorption — take with food to compensate
• Oral contraceptives: Gut flora disruption may reduce efficacy; use additional barrier contraception
• Metformin: No direct interaction; hold if acute kidney injury develops during severe infection

Side Effects

Adding clavulanic acid to cefuroxime increases GI side effect frequency compared to plain cefuroxime:

• Very common: Diarrhoea, nausea — particularly if taken on an empty stomach
• Common: Vomiting, abdominal cramps, rash, headache
• Uncommon: Elevated liver enzymes (ALT/AST), cholestatic jaundice (rare but more common with clavulanate-containing products than plain cephalosporins)
• Rare: Anaphylaxis, Stevens-Johnson syndrome, Clostridioides difficile-associated colitis

Contraindications

• Hypersensitivity to cefuroxime, clavulanic acid, penicillins, or any cephalosporin
• History of jaundice or hepatic dysfunction associated with previous clavulanate use
• Severe immediate penicillin hypersensitivity (cross-reactivity risk)

Frequently Asked Questions (FAQ)